SB366791

**SB366791** is a potent and highly selective small molecule antagonist of the transient receptor potential vanilloid 1 (TRPV1) ion channel. TRPV1, also known as the capsaicin receptor, is a non-selective cation channel involved in the detection of noxious stimuli including heat, acid, and capsaicin. SB366791 competitively inhibits TRPV1 through high-affinity binding at the vanilloid binding site located between the S1-S4 and S5-pore domains on the receptor, blocking activation by various stimuli. Unlike earlier TRPV1 antagonists, SB366791 demonstrates a high selectivity profile, showing minimal off-target activity in binding and electrophysiological assays. It has been investigated as a tool compound in pain, itch (pruritus), and addiction research. In animal studies, SB366791 alone does not produce antinociceptive effects in naïve models but can reduce pruritus induced by morphine and potentiates the analgesic effects of opioids in pain models (such as bone cancer pain). Studies also show it decreases morphine self-administration, indicating a potential role in addiction research. The drug is used primarily in research settings and is not approved for clinical use[1][2][3][4][5][6][8][11].